Using pharmacogenetics to personalize treatment outcome to ranibizumab (Lucentis) for the eye disease age-related macular degeneration (AMD)

药物Lucentis给老年性黄斑变性的治疗带来了革命性的变化，老年性黄斑变性是澳大利亚严重视力丧失的最常见原因之一。不幸的是，尽管进行了这种治疗，仍有多达25%的患者继续失明。我们将使用最新的基因芯片技术来识别导致这种不良反应的遗传变异。拥有这些信息将使我们能够对患者进行个性化治疗，从而改善他们的视力。

The drug Lucentis has revolutionized the treatment of age-related macular degeneration, one of the commonest causes of severe vision loss in Australia. Unfortunately, up to 25% of patients continue to lose vision despite this treatment. We will use the latest gene chip technology to identify the genetic variant responsible for this poor response. Having this information will allow us to personalise treatment for the patient leading to improvement in their vision.